

# Rachel Perret

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7767579/publications.pdf>

Version: 2024-02-01

13  
papers

643  
citations

1040056

9  
h-index

1372567

10  
g-index

13  
all docs

13  
docs citations

13  
times ranked

1362  
citing authors

#	ARTICLE	IF	CITATIONS
1	MicroRNA-155 Is Required for Effector CD8+ T Cell Responses to Virus Infection and Cancer. <i>Immunity</i> , 2013, 38, 742-753.	14.3	278
2	Adjuvants That Improve the Ratio of Antigen-Specific Effector to Regulatory T Cells Enhance Tumor Immunity. <i>Cancer Research</i> , 2013, 73, 6597-6608.	0.9	86
3	Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. <i>European Journal of Immunology</i> , 2011, 41, 2217-2228.	2.9	69
4	Effector lymphoid tissue and its crucial role in protective immunity. <i>Trends in Immunology</i> , 2005, 26, 242-247.	6.8	36
5	Virus-like particles from rabbit hemorrhagic disease virus can induce an anti-tumor response. <i>Vaccine</i> , 2008, 26, 5334-5337.	3.8	34
6	CD1d-antibody fusion proteins target iNKT cells to the tumor and trigger long-term therapeutic responses. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 747-760.	4.2	34
7	T-cell intrinsic Toll-like receptor signaling: implications for cancer immunotherapy and CAR T-cells. , 2021, 9, e003065.		30
8	Dendritic Cells Treated with Lipopolysaccharide Up-Regulate Serine Protease Inhibitor 6 and Remain Sensitive to Killing by Cytotoxic T Lymphocytes In Vivo. <i>Journal of Immunology</i> , 2008, 181, 8356-8362.	0.8	19
9	Saponins from the Spanish saffron <i>Crocus sativus</i> are efficient adjuvants for protein-based vaccines. <i>Vaccine</i> , 2012, 30, 388-397.	3.8	19
10	iNKT/CD1d-antitumor immunotherapy significantly increases the efficacy of therapeutic CpG/peptide-based cancer vaccine. , 2014, 2, 39.		16
11	Effector CD8 <sup>+</sup> T cells activated <i>in vitro</i> confer immediate and long-term tumor protection <i>in vivo</i> . <i>European Journal of Immunology</i> , 2008, 38, 2886-2895.	2.9	14
12	Inefficient boosting of antitumor CD8 <sup>+</sup> T cells by dendritic-cell vaccines is rescued by restricting T-cell cytotoxic functions. <i>Oncolmmunology</i> , 2012, 1, 1507-1516.	4.6	6
13	Peptide and Protein-Based Cancer Vaccines. , 2013, , 111-146.		2